Clinical trials: Clinical Depression
Major Depressive Disorder
Changes in Cerebral Glucose Metabolism After Electroconvulsive Therapy (ECT)
There exist already a few studies that have measured changes of brain metabolism pre and post Electroconvulsive Therapy (ECT) by Positron emission tomography (PET) but these were all performed in a small number of patients and…
- Trial name
- NCT01514435
- Testing
- Electroconvulsive therapy, 18-Fluoro-desoxy-glucose positron emission tomography
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- Medical University of Graz
the Use of Antidepressants in Patients With Bipolar Depression
Guidance Model of Standardized Treatment of Antidepressants in Bipolar Disorder
The bipolar depression patients of 18-55 years old were recruited. At the time of enrollment, the demographic, symptomatic, neuropsychological, neurobiological and genetic data was collected.
- Trial name
- NCT03148535
- Testing
- Lithium Carbonate, lithium carbonate combined with SSRI antidepressant treatment
- Where
- 4 sites in China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peking University
Depression, Stress Disorders, Post-Traumatic
Self-Help Intervention for Post 9/11 Veterans With Depression or PTSD Symptoms
It is important to provide support and resources for the many post-9/11 Veterans with mental health symptoms and poor psychosocial functioning who do not engage in psychotherapy.
- Trial name
- NCT07202325
- Testing
- Resilience Training for Veterans (REST-V), Usual resources
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- VA Office of Research and Development
Bipolar Disorder
The Treatment of Children and Adolescents With Treatment-Resistant Depression
This study seeks to learn about brain function in adolescents with depression and to determine whether adding lithium carbonate to antidepressant medication can reduce depression in children and adolescents.
- Trial name
- NCT00029640
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine
The purpose of this study was to investigate the efficacy and safety of antidepressant augmentation with agomelatine in the treatment of patients with depression who did not demonstrate satisfying response to selective serotonin…
- Trial name
- NCT04589143
- Testing
- Agomelatine
- Where
- China
- Volunteers
- 137 people
- Sponsor
- Central South University
Chemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia
Gut Microbiome Profiles in Patients With Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544).
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of chemotherapy (CT), often requiring dose reductions or treatment interruptions, which can compromise efficacy of the planned CT…
- Conditions
- Chemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia, Numbness, Tingling
- Trial name
- OzoParQTmicrob (NCT06799351)
- Testing
- Ozone therapy
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- Bernardino Clavo, MD, PhD
Bipolar Disorder, Bipolar Depression
Ketamine for Treatment-Resistant Bipolar Disorder
Growing evidence has supported rapid and robust antidepressant effects with subanesthetic doses of intravenous (IV) ketamine for treatment resistant depression (TRD).
- Conditions
- Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
- Trial name
- KET-BD (NCT05004896)
- Testing
- Ketamine Hydrochloride, Midazolam Hydrochloride
- Where
- 3 sites in Canada
- Volunteers
- 71 people
- Sponsor
- Joshua Rosenblat
Treatment-resistant Depression (TRD)
Personalized DBS Targeting for Treating Depression
The goal of this clinical trial is to optimize the target brain areas for deep brain stimulation (DBS) for depression based on personalized brain imaging and stereo-electroencephalography（SEEG), to administer long-term DBS…
- Trial name
- NCT06784388
- Testing
- Deep Brain Stimulation(DBS), Esketamine
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Major Depression
Efficacy of 18-Months of Antidepressive Medication Plus CBT or Dynamic or Supportive Psychotherapy for Recurrent Major Depression
Major Depressive Disorder affects approximately 16% of the adult population over the lifetime. Controlled studies indicate that short-term antidepressive medications or psychotherapy produce full remission in only about 46% of…
- Trial name
- NCT00220623
- Testing
- antidepressant medications, flexible drug choice, CBT, Psychodynamic or Supportive Psychotherapy
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Major Depression, Dementia
Neurocognitive Outcomes of Depression in the Elderly
Late-life depression (LLD) and cognitive impairment (CI) are significant public health problems among older adults, and their co-occurrence markedly increases disease burden and dementia risk.
- Trial name
- NCODE (NCT00570583)
- Where
- United States
- Volunteers
- 795 people, healthy volunteers welcome
- Sponsor
- Duke University
Major Depressive Disorder (MDD), Physical Activity
Lifestyle Interventions to Prevent Cognitive Deficits in Subjects With Depressive Symptoms: From Mechanisms to Clinical Practice
The goal of this clinical study is to investigate if lifestyle changes can help prevent cognitive decline and reduce depressive symptoms in people between the ages of 50 and 80 with depressive symptoms or a diagnosis of major…
- Conditions
- Major Depressive Disorder (MDD), Physical Activity, Inflammation, Metabolome
- Trial name
- POWER (NCT07009223)
- Testing
- Mediterranean Diet, Physical Activity, Cognitive Training
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Depressive Disorder, Treatment-Resistant
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression
This study evaluated the efficacy and safety of the compound MIJ821 compared to placebo in patients aged from 18 to 65 years diagnosed with treatment-resistant depression. The study was conducted in the US and in Europe (Spain).
- Trial name
- NCT03756129
- Testing
- MIJ821, Ketamine
- Where
- 12 sites in United States, Spain
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Depressive Disorder, Depressive Disorder, Major Depressive Disorder
Detection Algorithm for Recurrence or Relapse of Depression Thanks to a Smartwach
Globally, 3.8% of the population, or approximately 280 million people, suffer from depression. In France, 12.5% of adults experienced a major depressive episode (MDE) in 2021, with women being twice as affected as men.
- Conditions
- Depressive Disorder, Depressive Disorder, Major Depressive Disorder, Depressive Disorder Not Otherwise Specified (NOS)
- Trial name
- DALIA (NCT06789822)
- Testing
- Invitation to wear the smartwatch
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Dalia Care
Unipolar Depression
Effects of Repeated Attachment Security Priming on Depressed Mood: a Clinical Study
The purpose of this study is to explore whether asking participants to visualise a secure attachment figure or a neutral event leads to differences in self-reported felt security or depressed mood.
- Trial name
- NCT01694030
- Testing
- Attachment security priming
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University of Southampton
Stimulant Use, Human Immunodeficiency Virus (HIV)
Project neuroARTEMIS
The purpose of this research is to understand how chronic stress affects the way our brain and immune systems function, and in turn how this affects the way people feel, think, and behave.
- Conditions
- Stimulant Use, Human Immunodeficiency Virus (HIV), Depression
- Trial name
- NCT06814275
- Testing
- ARTEMIS, Contingency management for Antiretroviral (ARV) adherence
- Where
- United States
- Volunteers
- 189 people
- Sponsor
- Wake Forest University Health Sciences
Depression, Interpersonal Relations
IPT-based Group Intervention by Non-specialist for Improvement of Depressive Symptoms in Community Young Adults in Brazil
Major depressive disorder is a highly prevalent, recurrent, and debilitating disease, the third cause of years of lost life in the world, and it may be the most common disease in 2030, according to the World Health Organization…
- Trial name
- NCT06480019
- Testing
- Interpersonal psychotherapy
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Major Depressive Disorder
Clinical Study of Generic and Brand Bupropion in Depression
Determine bioequivalence between branded and generic bupropion extended release (XL) products (and between generic products) at steady state in patients with major depressive disorder.
- Trial name
- BALANCE (NCT02209597)
- Testing
- Bupropion XL 300
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Washington University School of Medicine
Depressive Disorder
A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)
The purpose of the study is to evaluate the long-term efficacy and safety of Saredutant in patients with depression. The primary objective is to evaluate the efficacy and safety of Saredutant 100 mg once daily compared to placebo…
- Trial name
- NCT00336713
- Testing
- Saredutant (SR48968C)
- Where
- United States
- Volunteers
- 430 people
- Sponsor
- Sanofi
Borderline Personality Disorder
Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder
Selegiline is superior to placebo in improving psychological and physical functioning in patients with Borderline Personality Disorder.
- Trial name
- NCT01912391
- Testing
- Selegiline
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mood and Anxiety Research, Inc
Bipolar Affective Disorder
rTMS in the Treatment of Bipolar Depression
Bipolar affective disorder (BPAD) is: A serious mental illness Estimated to be present in as high as 6.4% of the population in Western populations Associated with considerable disability and high morbidity.
- Trial name
- NCT00436020
- Testing
- TMS
- Where
- Australia
- Volunteers
- 51 people
- Sponsor
- Bayside Health